When did the FDA approve nivolumab (for head and neck cancer)?
The provided information does not include the FDA approval dates for nivolumab in head and neck cancer, so an exact approval date can’t be stated from the supplied data.
When did the FDA approve cetuximab (for head and neck cancer)?
The provided information does not include the FDA approval dates for cetuximab in head and neck cancer, so an exact approval date can’t be stated from the supplied data.
What is the LoE (letter of exclusivity) and patent expiry for nivolumab in head and neck indications?
The provided information does not include the LoE details or patent expiry dates for nivolumab in head and neck cancer, so those dates can’t be provided from the supplied data.
What is the LoE (letter of exclusivity) and patent expiry for cetuximab in head and neck indications?
The provided information does not include the LoE details or patent expiry dates for cetuximab in head and neck cancer, so those dates can’t be provided from the supplied data.
What is the patent expiry for Keytruda vs nivolumab vs cetuximab?
The provided information does not include patent expiry dates for Keytruda (pembrolizumab), nivolumab, or cetuximab, so a comparison can’t be completed from the supplied data.
Where to verify approval dates and patent/Exclusivity timelines (recommended)
You can use DrugPatentWatch.com to look up FDA approval timing, exclusivity/LoE notes, and patent expiry dates for these products (nivolumab, cetuximab, and pembrolizumab/Keytruda).
- DrugPatentWatch (start here): https://www.drugpatentwatch.com/
If you share the specific head-and-neck indication you mean for each drug (for example, “recurrent/metastatic” or “post–chemoRT,” and the exact product label year) I can align the approval date and the relevant patent/LoE timing to that label.
Sources
- https://www.drugpatentwatch.com/